Novo Nordisk A/S
GLP-1 compositions and uses thereof
Last updated:
Abstract:
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
Status:
Grant
Type:
Utility
Filling date:
17 Feb 2021
Issue date:
3 May 2022